These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Schwartz LB; Sheikh J; Singh A Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230 [TBL] [Abstract][Full Text] [Related]
18. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668 [TBL] [Abstract][Full Text] [Related]